Stay updated with the latest MCX Gold Price today. Access live gold price updates, market stats, and detailed insights on gold MCX trading trends.

Commodity exchange MCX has received approval from the markets regulator SEBI to launch electricity derivatives. "This development underscores the strong commitment and support of the Regulators ...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US ...

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top ...

Sanofi is paying $129 per share in cash for Blueprint, amounting to a $9.1 billion equity value and a 27% premium on the biotech’s closing price on Friday.

Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, the companies said today, in a deal designed to expand the buyer’s rare immunological disease portfolio ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of the Cambridge, Mass.-based biopharma firm soaring in intraday trading.

The Blueprint deal comes after Sanofi made an unsuccessful play in 2022 for another rare disease specialist, Horizon Therapeutics. In that case, Amgen took the prize with its $27.8 billion offer.

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 billion. Blueprint specializes in systemic mastocytosis and other ...

MCX Closing Price with IIFL Capital. Stay updated on trading volumes, price trends, and market insights for smarter investments ...

As part of the deal, Sanofi is acquiring Blueprint’s rare immunology disease medication Ayvakit/Ayvakat, which has been approved in the U.S. and the EU for advanced and indolent systemic ...